» Articles » PMID: 20433807

Antibody Response Against Heterogeneous Circulating Influenza Virus Strains Elicited by MF59- and Non-adjuvanted Vaccines During Seasons with Good or Partial Matching Between Vaccine Strain and Clinical Isolates

Overview
Journal Vaccine
Date 2010 May 4
PMID 20433807
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

MF59 is already known to enhance the breadth of antibody response to mismatched influenza seasonal and avian strains. However, little is known on the effect of MF59 on immunogenicity of influenza vaccines when "apparent" good matching between circulating and vaccine strains exists. To this end, we compared the immune response elicited by MF59-adjuvanted or non-adjuvanted subunit vaccine, containing A/California/7/04(H3N2) strain, against circulating viruses isolated between 2004/2005 and 2006/2007 seasons, belonging to different clades. The advantage offered by MF59 in terms of higher immunogenicity, expressed as higher post-vaccination HI titres, is observable also against viruses showing antigenic and molecular pattern undistinguishable from vaccine strain, but it became even more evident as the antigenic and molecular distance between vaccine and circulating strains grew. These data show that seasonal influenza vaccine adjuvanted with MF59 can offer a stronger benefit as compared to non-adjuvanted vaccine in protecting against a broader range of virus strains circulating during the influenza season.

Citing Articles

Immunogenicity and safety of the MF59-adjuvanted seasonal influenza vaccine in non-elderly adults: A systematic review and meta-analysis.

Domnich A, Trombetta C, Fallani E, Salvatore M PLoS One. 2025; 19(12):e0310677.

PMID: 39775353 PMC: 11684710. DOI: 10.1371/journal.pone.0310677.


Relative Effectiveness of the MF59®-Adjuvanted Influenza Vaccine Versus High-Dose and Non-Adjuvanted Influenza Vaccines in Preventing Cardiorespiratory Hospitalizations During the 2019-2020 US Influenza Season.

Imran M, Puig-Barbera J, Ortiz J, Lopez-Gonzalez L, Dean A, Bonafede M Influenza Other Respir Viruses. 2024; 18(4):e13288.

PMID: 38644564 PMC: 11033326. DOI: 10.1111/irv.13288.


Immunogenicity of Enhanced Influenza Vaccines Against Mismatched Influenza Strains in Older Adults: A Review of Randomized Controlled Trials.

Youhanna J, Tran V, Hyer R, Domnich A Influenza Other Respir Viruses. 2024; 18(4):e13286.

PMID: 38594827 PMC: 11004266. DOI: 10.1111/irv.13286.


Antibody responses against heterologous H5N1 strains for an MF59-adjuvanted cell culture-derived H5N1 (aH5n1c) influenza vaccine in adults and older adults.

Frey S, Versage E, Van Twuijver E, Hohenboken M Hum Vaccin Immunother. 2023; 19(1):2193119.

PMID: 37057755 PMC: 10114991. DOI: 10.1080/21645515.2023.2193119.


Surveillance of Severe Acute Respiratory Infection and Influenza Vaccine Effectiveness among Hospitalized Italian Adults, 2021/22 Season.

Panatto D, Domnich A, Chironna M, Loconsole D, Napoli C, Torsello A Vaccines (Basel). 2023; 11(1).

PMID: 36679928 PMC: 9861626. DOI: 10.3390/vaccines11010083.